Drug intelligence / Profile preview

AllerR

Development stage: Preclinical
Lead developer: HAL Allergy
Modality: Peptides, Vaccines & Immunotherapeutics

Overview

AllerR is an allergy vaccine candidate developed by the Swiss biopharmaceutical company Anergis. It is based on Anergis's proprietary Continuous Overlapping Peptides (COPs) technology, which is designed to create synthetic immunotherapies for allergies. AllerR was part of Anergis's pipeline assets intended for clinical development.

Targets

TCR (T cell antigen receptor complex)

Beyond the preview

Go deeper on AllerR.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AllerR.

Explore the full profile